Company intelligence / Profile preview
Inimmune Corporation
Missoula, Montana, United Statesinimmune.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Successfully completed Phase 1 clinical trial for intranasal INI-2004 for allergic rhinitis, which was safe and well-tolerated with no drug-related serious adverse events and showed dose-related improvement in nasal congestion compared to placebo. Currently enrolling patients in Phase 1 oncology clinical trial using INI-4001 (TLR7/8) monotherapy in a nanoparticle formulation[4].
- Therapeutic areas
- OncologyImmunologyPsychiatryInfectious Diseases
- Modalities
- ImmunotherapeuticsVaccine adjuvants
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
SPI Pharma, Inc. (strategic collaboration to develop and commercialize advanced adjuvant systems for vaccine development)[3][4]
Beyond the preview
Go deeper on Inimmune Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inimmune Corporation.